Herti 150mg (Trastuzumab)

About Herti 150mg (Trastuzumab)

Herti 150 mg contains Trastuzumab, a monoclonal antibody that is used primarily in the treatment of certain types of breast cancer and gastric cancer that overexpress a protein called HER2 (human epidermal growth factor receptor 2). This protein is involved in the growth and spread of cancer cells, and targeting it with Trastuzumab helps inhibit cancer cell growth.

Indications

Trastuzumab (Herti) is most commonly used to treat:

• HER2-positive breast cancer: This includes both early-stage and metastatic (advanced) breast cancer that tests positive for HER2 overexpression.
• HER2-positive gastric cancer: It is also used to treat gastric cancer that overexpresses the HER2 protein, especially when the cancer has spread to other parts of the body.

Mechanism of Action

Trastuzumab works by binding to the HER2 receptor on the surface of cancer cells. By binding to this receptor, it does two main things:

1. Inhibits HER2 signaling: Blocking the receptor prevents the cancer cells from receiving the signals they need to grow and divide.
2. Immune system activation: Trastuzumab also helps the immune system recognize and attack the cancer cells by promoting antibody-dependent cellular cytotoxicity (ADCC), where immune cells destroy the targeted cancer cells.

Dosage and Administration

• Dosage: The dose of Trastuzumab depends on the specific cancer being treated, and it is usually based on the patient's body surface area. A typical dose for breast cancer may start at 8 mg/kg given intravenously once a week or every three weeks for the first dose, followed by maintenance doses of 6 mg/kg every 3 weeks.

  For gastric cancer, the typical starting dose might be 8 mg/kg for the first infusion, followed by 6 mg/kg every 3 weeks.

  The infusion is typically administered intravenously (IV), although subcutaneous formulations are also available for certain indications.

• Administration: Trastuzumab is typically administered in a healthcare setting, such as a hospital or oncology clinic, to ensure that any infusion-related reactions can be managed immediately.

Side Effects

Common side effects include:

• Infusion-related reactions: These may include fever, chills, nausea, vomiting, and headache. These reactions are typically seen during the first few infusions.
• Fatigue: Many patients report feeling tired or weak.
• Diarrhea
• Pain: Joint pain or muscle pain can also occur.

Serious side effects can include:

• Heart problems: Trastuzumab can lead to heart failure or other cardiac issues, especially in patients with pre-existing heart conditions. Heart function is typically monitored through regular echocardiograms or other cardiac tests during treatment.
• Lung problems: Trastuzumab may cause or worsen lung issues, including interstitial lung disease or pulmonary toxicity.
• Infections: Trastuzumab may increase the risk of infections due to its effects on the immune system.

Precautions and Warnings

• Cardiac monitoring: Because Trastuzumab can affect heart function, heart monitoring is important, especially in patients with a history of heart disease. Ejection fraction (EF) tests (such as echocardiograms) are typically performed to assess heart function before and during treatment.
• Infusion-related reactions: Severe infusion reactions, including anaphylaxis, can occur. Monitoring is done during the infusion to manage any reactions.
• Pregnancy and breastfeeding: Trastuzumab can harm a developing fetus, so it should not be used during pregnancy unless absolutely necessary. It is also contraindicated during breastfeeding as it can pass into breast milk.
• Liver function: Regular liver function tests are recommended, as liver toxicity can occur in some cases.

Important Considerations

• Long-term use: Trastuzumab is often used in combination with other treatments, such as chemotherapy or hormone therapy, and may be part of a longer-term treatment regimen for HER2-positive cancers.
• Cancer progression: Trastuzumab is usually well-tolerated, but in rare cases, the cancer may develop resistance to it. If this happens, doctors may adjust the treatment plan or consider alternative therapies.

Conclusion

Herti (Trastuzumab) is a targeted therapy that has significantly improved the outcomes for patients with HER2-positive breast and gastric cancers. Although it is generally well-tolerated, it requires careful monitoring for heart function and infusion-related reactions. Its an essential part of the modern treatment landscape for certain types of cancer, helping to slow or stop the growth of cancer cells and improve survival rates.

Targeted Cancer Therapy

Herti 150mg, containing trastuzumab, is specifically formulated to target HER2 receptor-positive cancer cells. By binding to these receptors, it helps inhibit the growth and spread of certain breast and gastric cancers. Delivered as an intravenous infusion, this medication provides a precise treatment option for patients with HER2-positive diagnoses, focusing on advancing oncological care with recombinant DNA technology.


Safe Preparation and Administration

This product arrives as a lyophilized powder, ensuring stability until reconstitution. Medical professionals must reconstitute Herti 150mg using bacteriostatic water for injection, then dilute and administer it as an IV infusion. The process is strictly supervised in clinical settings to maximize effectiveness and minimize risk, offering assurance through controlled and safe handling.


Storage and Handling

To preserve its pharmaceutical integrity, Herti 150mg should be stored at temperatures between 2C and 8C, and must not be frozen. Packaged in an unopened, transparent glass vial with a rubber stopper, this product maintains its efficacy when properly handled. Always ensure the seal is intact before use and only use under medical supervision.